Navigation Links
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
Date:12/9/2008

atients in this group could receive all six of the intended courses compared with an historic high-risk group treated with FCR. There was no significant difference in incidence of infection during treatment with CFAR compared to FCR, with the exception of cytomegalovirus (CMV) reactivation. Follow-up continues for the patients treated on this trial to evaluate responses in all 60 enrolled patients and time-to-event endpoints.

Abstract #329

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

The multicenter trial evaluated subcutaneous alemtuzumab given three times weekly at 30 mg in fludarabine refractory CLL. From September 2002 to February 2006, 103 patients were enrolled and received at least one dose of alemtuzumab. Median age was 63 years.

Subcutaneous treatment was performed on an outpatient basis in 96 percent of patients and had to be temporarily interrupted in 65 patients due to neutropenia (27 percent), anemia (three percent), thrombocytopenia (eight percent), infections (36 percent), and was stopped early in 65 cases due to insufficient response (43 percent), hematotoxicity (14 percent) and infections (29 percent). The median alemtuzumab dose given was 722 (3-2203) mg.

Toxicity observed during the treatment period was mostly grade 1/2 apart from hematotoxicity. Grade 3/4 neutropenia, thrombocytopenia, and anemia occurred in 56 percent, 57 percent, and 50 percent of patients, respectively. Grade 3/4 non-CMV infection occurred in 29 percent. CMV reactivation was observed in 15 percent total. Grade 3/4 occurred in eight percent of patients. All CMV episodes were successfully treated with anti-CMV therapy, and there was no CMV-related death. Injection site reactions occurred in 34 percent of patients and were grade 1 or 2 except in one patient
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... DIEGO , Feb. 26, 2015  Tandem Diabetes ... device company and manufacturer of the t:slim® and t:flex™ ... public offering of 5,250,000 shares of its common stock ... share.  The net proceeds to Tandem from this offering ... discounts and commissions and other estimated offering expenses payable ...
(Date:2/26/2015)... 2015  Mobility Ventures LLC, an AM General Company, ... America (NYSE: BAC ) that will make ... the revolutionary MV-1 - - the world,s first and ... to provide safe and comfortable transportation for all passengers ... to purchase a new MV-1 vehicle at the over ...
(Date:2/26/2015)... , February 26, 2015 ... Outlook 2015: First -In- Class Innovations and Cost ... for Large Cap Pharmaceutical Companies research report to ... According to this Global Pharma US & ... as productivity measurements, divestment of non-core assets result ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 4
... Germany, January 18, 2012 Eppendorf AG ... to Bibby Scientific for use e.g. in their TC ... 7,074,367. Eppendorf utilizes the technology in its Eppendorf Mastercycler® ... models. Eppendorf AG, based in Hamburg, Germany, ...
... Takeda Pharmaceutical Company Limited ("Takeda", TSE: ... global workforce and consolidate site operations in order to ... than 70 countries, adapt to changing market conditions and ... as outlined in its 2011-2013 Mid-Range Plan (MRP). ...
Cached Medicine Technology:Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 2Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 3Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 4Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 5
(Date:2/28/2015)... California (PRWEB) February 28, 2015 Plugin ... of TransFold Volume 2. A fully customizable transition ... , “TransFold Volume 2 gives users total control over ... Christina Austin, CEO of Pixel Film Studios. “TransFold Volume ... X editor.” , TransFold Volume 2 from Pixel Film ...
(Date:2/28/2015)... My Shiney Hiney® LLC., the renowned brand ... Las Vegas, Nevada for the annual ASD Market Week tradeshow. ... leading consumer-goods tradeshows and My Shiney Hiney will be one ... Shiney Hiney can be found at booth number C1663. , ... at-home personal hygiene brush and cleansing system exclusively created to ...
(Date:2/27/2015)... February 27, 2015 Wireless Analytics, ... services, and one of the founders of ... for Bell Mobility within their CLEAN Platform™ (Communications ... Wireless Analytics’ newly developed Bell Mobility Data ... the Canadian wireless carrier’s business customers. , Wireless ...
(Date:2/27/2015)... Beverly Hills, CA (PRWEB) February 27, 2015 ... was in the air for those suffering from Sjögren’s ... had been discovered by researchers at the University of ... the next phase of research was to develop a ... to precisely detect the presence of new autoantibodies. Researchers ...
(Date:2/27/2015)... MD (PRWEB) February 27, 2015 ... (Meso Foundation) and the National Cancer Institute (NCI) ... Mesothelioma at the National Institutes of Health (NIH), ... one part is dedicated to medical professionals and ... is directed to the general public, including patients, ...
Breaking Medicine News(10 mins):Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3
... (HealthDay News) -- Asthma and chronic obstructive pulmonary disease ... face a significantly higher relative risk for both the ... The warning stems from an analysis of data ... use was associated with a 34 percent increase in ...
... HealthDay Reporter , WEDNESDAY, Dec. 15 (HealthDay News) ... States has declined 28 percent since the late 1990s, but ... deaths, a new study finds. And the cost of ... or any other diagnostic group, an estimated $286 billion in ...
... Reinberg HealthDay Reporter , WEDNESDAY, Dec. 15 (HealthDay News) ... had both leukemia and AIDS no longer has any detectable HIV ... leukemia three years ago. But experts were quick to ... treatment of AIDS worldwide. As it turns out, the ...
... infected at some time in their lives with Epstein-Barr virus ... immune systems, such as people with organ transplants or HIV ... this virus. Scientists at the Duke Cancer Institute have ... EBV infections, a finding that has implications for understanding the ...
... received a 2010 Web Health Award for its patient-geared ... is a national competition that recognizes high-quality electronic health ... competition from a variety of health care professionals nationwide. ... electronic health information experts., This year, ASTRO received a ...
... , WEDNESDAY, Dec. 15 (HealthDay News) -- A group that ... to watch for attempted suicides in patients with no history ... by the Joint Commission, stresses that it,s not just psychiatric ... diagnosed with cancer who goes to an ER because the ...
Cached Medicine News:Health News:Inhalers Linked to Higher Odds of Diabetes in Asthma, COPD Patients 2Health News:Inhalers Linked to Higher Odds of Diabetes in Asthma, COPD Patients 3Health News:Death Rate From Heart Disease, Stroke Drops Off Over Decade 2Health News:Death Rate From Heart Disease, Stroke Drops Off Over Decade 3Health News:Docs Claim Transplant Cured Man of HIV, But Experts Urge Caution 2Health News:Docs Claim Transplant Cured Man of HIV, But Experts Urge Caution 3Health News:Scientists decode secrets of a very common virus that can cause cancer 2Health News:Severe Pain Can Trigger Suicide in Hospital ERs 2Health News:Severe Pain Can Trigger Suicide in Hospital ERs 3
... coded patient identification bracelets (wristbands) and/or ... at patient care areas throughout the ... identification and in creating a positive ... back to the patient through the ...
The IDENTI-PRINT II ID system functions as a complete, hospital wide patient identification system. It integrates the benefits of bedside labeling into a multipurpose ID band that consolidates admitt...
... Volks drive to provide ... to bring you a lens ... in a non-contact slit lamp ... true 3D viewing of the ...
... compact RFID printing solution that can encode ... the R2844-Z printer/encoder is one of the ... printing and encoding smart media such as ... the needs of applications requiring greater processing ...
Medicine Products: